HN2002000376A - Metodos para granulacion humeda de azitromicina - Google Patents

Metodos para granulacion humeda de azitromicina

Info

Publication number
HN2002000376A
HN2002000376A HN2002000376A HN2002000376A HN2002000376A HN 2002000376 A HN2002000376 A HN 2002000376A HN 2002000376 A HN2002000376 A HN 2002000376A HN 2002000376 A HN2002000376 A HN 2002000376A HN 2002000376 A HN2002000376 A HN 2002000376A
Authority
HN
Honduras
Prior art keywords
azitromycin
methods
wet granulation
granulation
dihydrate azithromycin
Prior art date
Application number
HN2002000376A
Other languages
English (en)
Inventor
Michael Ruce Fergione
Barbara Alice Johnson
Original Assignee
Pfier Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfier Products Inc filed Critical Pfier Products Inc
Publication of HN2002000376A publication Critical patent/HN2002000376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN METOD DE FORMACION DE GRANULOIS DE AZITROMICINA DE DIHIDRATO, QUE COMPRENDE MEZCLAR PARTICULAS DE AZITROMICINA NO DIHIDRATO, CON UNA CANTIDAD DE GRANULACION DE UN LIQUIDO DE GRANULACION.
HN2002000376A 2001-12-21 2002-12-19 Metodos para granulacion humeda de azitromicina HN2002000376A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34346901P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
HN2002000376A true HN2002000376A (es) 2003-02-21

Family

ID=23346249

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2002000376A HN2002000376A (es) 2001-12-21 2002-12-19 Metodos para granulacion humeda de azitromicina

Country Status (21)

Country Link
US (1) US20030190365A1 (es)
EP (1) EP1455757A2 (es)
JP (1) JP2005515212A (es)
KR (1) KR100669279B1 (es)
CN (1) CN1606433A (es)
AR (1) AR037931A1 (es)
AU (1) AU2002353316A1 (es)
BR (1) BR0215175A (es)
CA (1) CA2470055A1 (es)
HN (1) HN2002000376A (es)
IL (1) IL161259A0 (es)
MX (1) MXPA04003027A (es)
NO (1) NO20042575L (es)
NZ (1) NZ532063A (es)
PA (1) PA8562101A1 (es)
PE (1) PE20030588A1 (es)
PL (1) PL371125A1 (es)
RU (1) RU2283651C2 (es)
TW (1) TW200301260A (es)
WO (1) WO2003053399A2 (es)
ZA (1) ZA200402586B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
RU2331410C2 (ru) 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
WO2005053651A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
MXPA06006887A (es) * 2003-12-23 2006-09-04 Temrel Ltd Proceso para producir particulas para composiciones farmaceuticas.
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
AU2009316876A1 (en) * 2008-11-20 2011-07-07 Avantor Performance Materials, Inc. Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
RU2403049C1 (ru) * 2009-06-04 2010-11-10 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава) Способ получения таблеток эритромицина
EP2295037A1 (en) * 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin
RU2480689C1 (ru) * 2011-10-26 2013-04-27 Александр Михайлович Муртищев Способ получения порошкообразных продуктов
MX380123B (es) * 2016-01-27 2025-03-11 Jiangsu Hengrui Medicine Co Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo.
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
CN110292567B (zh) * 2019-05-17 2022-02-18 北京悦康科创医药科技股份有限公司 一种阿奇霉素胶囊的制备方法
CN113088422A (zh) * 2021-05-18 2021-07-09 耿艳飞 一种荞麦果醋
CN113559073A (zh) * 2021-07-20 2021-10-29 海南海神同洲制药有限公司 阿奇霉素片剂及其制备方法
CN116930013A (zh) * 2023-07-28 2023-10-24 海南卫康制药(潜山)有限公司 一种阿奇霉素干混悬剂中原料粒度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
US6245903B1 (en) * 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
US6365574B2 (en) * 1998-11-30 2002-04-02 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
US6703372B1 (en) * 1999-06-29 2004-03-09 Biochemie S.A. Macrolides
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
WO2003032922A2 (en) * 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
EP1455757A2 (en) 2004-09-15
PA8562101A1 (es) 2005-02-04
PL371125A1 (en) 2005-06-13
WO2003053399A2 (en) 2003-07-03
JP2005515212A (ja) 2005-05-26
AU2002353316A1 (en) 2003-07-09
MXPA04003027A (es) 2004-07-05
RU2283651C2 (ru) 2006-09-20
NO20042575L (no) 2004-06-18
TW200301260A (en) 2003-07-01
PE20030588A1 (es) 2003-07-08
KR20040073504A (ko) 2004-08-19
US20030190365A1 (en) 2003-10-09
CA2470055A1 (en) 2003-07-03
RU2004118502A (ru) 2005-04-10
WO2003053399A3 (en) 2004-05-21
AR037931A1 (es) 2004-12-22
ZA200402586B (en) 2005-04-01
NZ532063A (en) 2006-03-31
IL161259A0 (en) 2004-09-27
CN1606433A (zh) 2005-04-13
BR0215175A (pt) 2004-12-28
KR100669279B1 (ko) 2007-01-16

Similar Documents

Publication Publication Date Title
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
DK1427910T3 (da) Cheleringssammensætninger til fraktureringsvæske
HN2002000038A (es) Compuestos triazolo como inhibidores de mmp.
BR0200653B1 (pt) ferramenta de diamante.
DE60115688D1 (de) Zementverrohrungsschuh für einzeldurchmesserbohrloch
CO5721017A2 (es) Composicion limpiadora que contiene un plomero hidrofilizado
CY1108791T1 (el) Φυτοενδυναμωτικο μεσον
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
BR0101437A (pt) Método para preparar um ciclopropeno
PT1339703E (pt) Processo para a preparacao de paclitaxel
UY26594A1 (es) Proceso para la simple preparación de (3-cloro-4fluorofenilo)-(7-(3-morfolina-4-ilopropoxi)-6-nitroquinazolna-4ilo)-amina o (3-cloro-4-fluorofenilo)-(7-(3-morfolina-4-il-propoxi)-6-aminoquinazolina-4-ilo)-amina.
ES1049589Y (es) Agitador para productos quimicos.
PT1372636E (pt) Dosagem metronomica para taxanos
ES1046152Y (es) Herramienta para reparacion de calzado.
ES1049353Y (es) Brandilla guarda-cuerpos para edificios.
DK1315702T3 (da) Fremgangsmåde til fremstilling af halogen-4-phenoxyquinoliner
ES1054650Y (es) Acoplamiento rapido, para union hermetica de tuberias
BR0300927B1 (pt) processo para construÇço de paredes prÉ-fabricadas por empilhamento, portantes ou nço, para edificaÇÕes.
ES1049092Y (es) Dispositivo de alineacion para encofrados de hormigon.
HN2000000168A (es) Gen de striptomyces avermitilis que dirigen la relacion de avermectinas b2:b1
ES1050514Y (es) Moldeadora de hormigon para cunetas.
ES1048341Y (es) Aplicador de conexiones para tuberias de riego.
IT1315792B1 (it) Regolo puntatore per parabole satellitari.
ATA3192000A (de) Stammblatt für dünnschnitt-kreissägen
ITMI20010456V0 (it) Mescolatore per calcestruzzo.